Cargando…

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

Targeted therapy is lagging behind in esophageal adenocarcinoma (EAC). To guide the development of new treatment strategies, we provide an overview of the prognostic biomarkers in resectable EAC treated with curative intent. The Medline, Cochrane and EMBASE databases were systematically searched, fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creemers, Aafke, Ebbing, Eva A., Pelgrim, Thomas C., Lagarde, Sjoerd M., van Etten-Jamaludin, Faridi S., van Berge Henegouwen, Mark I., Hulshof, Maarten C. C. M., Krishnadath, Kausilia K., Meijer, Sybren L., Bijlsma, Maarten F., van Oijen, Martijn G. H., van Laarhoven, Hanneke W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125467/ https://www.ncbi.nlm.nih.gov/pubmed/30185893 http://dx.doi.org/10.1038/s41598-018-31548-6

Ejemplares similares

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
por: Ebbing, Eva A., et al.
Publicado: (2019)

Chemoradiation induces epithelial‐to‐mesenchymal transition in esophageal adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2019)

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
por: Soeratram, Tanya TD, et al.
Publicado: (2021)

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract
por: Damhofer, Helene, et al.
Publicado: (2015)

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
por: Steins, Anne, et al.
Publicado: (2017)

(18)F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making
por: Anderegg, Maarten C. J., et al.
Publicado: (2015)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Microscopic tumor spread beyond (echo)endoscopically determined tumor borders in esophageal cancer
por: Machiels, Melanie, et al.
Publicado: (2019)

Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study
por: Jelvehgaran, Pouya, et al.
Publicado: (2018)

Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment
por: Hagens, Eliza R.C., et al.
Publicado: (2020)

The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth
por: Manoukian, Paul, et al.
Publicado: (2021)

Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2022)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

On the Receiving End of Autonomy and Law
por: van Laarhoven, Hanneke W. M., et al.
Publicado: (2017)

Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies
por: Hoefnagel, Sanne J. M., et al.
Publicado: (2022)

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
por: Stroes, Charlotte I., et al.
Publicado: (2021)

COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

FOXO transcriptional activity is associated with response to chemoradiation in EAC
por: Creemers, A., et al.
Publicado: (2022)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
por: van den Ende, Tom, et al.
Publicado: (2023)

Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer
por: Dings, Mark P.G., et al.
Publicado: (2022)

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
por: Noordman, Bo Jan, et al.
Publicado: (2015)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

The Use of (Network) Meta-Analysis in Clinical Oncology
por: ter Veer, Emil, et al.
Publicado: (2019)

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models
por: Li, Shulin, et al.
Publicado: (2022)

The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer
por: Doeve, Benthe H., et al.
Publicado: (2023)

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer
por: Veenstra, Veronique L., et al.
Publicado: (2018)

Author response to: Comment on: Outcomes after totally minimally invasive versus hybrid and open Ivor Lewis oesophagectomy: results from the International Esodata Study Group
por: van der Wilk, Berend J, et al.
Publicado: (2022)

Author response to: Outcomes after totally minimally invasive versus hybrid and open Ivor Lewis oesophagectomy: Results from the International Esodata Study Group
por: van der Wilk, Berend J, et al.
Publicado: (2022)

Author response to: Comment on: Outcomes after totally minimally invasive versus hybrid and open Ivor Lewis oesophagectomy: results from the International Esodata Study Group
por: van der Wilk, Berend J, et al.
Publicado: (2022)

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
por: Creemers, A., et al.
Publicado: (2017)

Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study
por: Dijksterhuis, Willemieke P M, et al.
Publicado: (2021)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Parents' knowledge of their child with profound intellectual and multiple disabilities: An interpretative synthesis
por: Kruithof, Kasper, et al.
Publicado: (2020)

Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: Hagens, E. R. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f6v7uq0t7u7bp0s9e5aubncovr